Influence of psychopathology and metabolic parameters on quality of life in patients with first-episode psychosis before and after initial antipsychotic treatment.
Anne Sofie A DahlVictor SørensenKaren S AmbrosenMikkel E SørensenGrímur H MohrMette Ø NielsenKirsten Borup BojesenBirte Yding GlenthøjMargaret K HahnJulie Midtgaard KlausenBjørn H EbdrupPublished in: Schizophrenia (Heidelberg, Germany) (2023)
The impact of psychological and physical health on quality of life (QoL) in patients with early psychosis remain relatively unexplored. We evaluated the predictive value of psychopathological and metabolic parameters on QoL in antipsychotic-naïve patients with first-episode psychosis before and after initial antipsychotic treatment. At baseline, 125 patients underwent assessments of psychopathology, prevalence of metabolic syndrome (MetS), and QoL. After 6 weeks of antipsychotic monotherapy, 89 patients were re-investigated. At baseline, the prevalence of MetS was 19.3% (n = 22). After 6 weeks, body weight (1.3 kg, p < 0.001) and body mass index (0.4 kg/m 2 , p < 0.001) increased, and four additional patients developed MetS. Multivariate linear regression revealed that positive and negative symptoms, and to some degree waist circumference, were predictors of QoL at both time points. Our findings suggest that in the earliest stages of antipsychotic treatment, metabolic side-effects may be less influential on QoL than psychopathological severity.
Keyphrases
- body mass index
- end stage renal disease
- body weight
- metabolic syndrome
- ejection fraction
- newly diagnosed
- healthcare
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- risk factors
- type diabetes
- clinical trial
- cardiovascular disease
- depressive symptoms
- patient reported outcomes
- skeletal muscle
- high resolution
- open label
- social media
- study protocol
- risk assessment
- human health
- smoking cessation
- gestational age
- single molecule